Abramson Cancer Center of the University of Pennsylvania
Last Modified: October 29, 2003
Contact Person: Janine Guglielmino or Alexa Blasdel
P: (610) 645-4567 or (215) 431-9332 (onsite)
WHO: Living Beyond Breast Cancer
WHAT: Free teleconference, "BREAKING NEWS: Letrozole, a New Treatment Option After Tamoxifen"
WHEN: Monday, November 3, 2003, 12:00 p.m. -1:00 p.m. EST
WHY: To provide women and families affected by breast cancer and their health care providers with vital new medical information about letrozole (brand name: Femara), a treatment recently found to significantly reduce the risk of recurrence in postmenopausal women with early stage, hormone-receptor positive breast cancer.
PROGRAM: A co-author of the large, international clinical trial of letrozole will explain in understandable language the study's significance and limitations and will take questions from participants on the call. Issues to be discussed include: who benefits from letrozole; how it works; how it differs from tamoxifen; how long letrozole should be used; its possible side effects; its effectiveness versus that of other aromatase inhibitors; and whether it benefits women who completed tamoxifen therapy more than six months ago.
SPEAKERS: Edith A. Perez, MD, co-author of the study; professor of medicine, Mayo Medical School; and director, Cancer Clinical Study Unit, Mayo Clinic, Jacksonville, Florida. The program moderator is Marisa C. Weiss, MD, radiation oncologist specializing in breast cancer, Lankenau Hospital/Jefferson Health System; founder, Living Beyond Breast Cancer; founder and president, breastcancer.org.
COST: Free; pre-registration required
SPONSOR: Funded by an unrestricted educational grant from Novartis Oncology
REGISTER: Fill out an online registration form at the web site of Living Beyond Breast Cancer, or call the LBBC office at (610) 645-4567.
Living Beyond Breast Cancer, founded in 1991, is dedicated to empowering all women affected by breast cancer to live as long as possible with the best quality of life. LBBC's programs include large-scale conferences; teleconferences; the toll-free Survivors' Helpline (888-753-5222); a web site; a quarterly newsletter; Project Connect, a community outreach program; the Young Survivors Network, an educational program for women diagnosed before age 45; and workshops for health care providers.
Nov 17, 2011 - Breast cancer survivors have significantly reduced activation of the prefrontal cortex, with additional reductions in prefrontal function and poorer executive functioning for women treated with chemotherapy, according to a study published in the November issue of the Archives of Neurology.
Mar 2, 2011
Oct 5, 2010
Jan 27, 2015